A prospective, single-center investigator-initiated study of Mavrilimumab for the treatment of patients COVID-19 infection
Latest Information Update: 07 Apr 2020
At a glance
- Drugs Mavrilimumab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 07 Apr 2020 New trial record
- 31 Mar 2020 According to a Kiniksa Pharmaceuticals media release, Professor Lorenzo Dagna, MD, FACP (Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy) plans to initiate a prospective, single-center investigator-initiated study of Mavrilimumab, based on the initial results from the treatment protocol (n=6).
Most Recent Events
Trial Overview
Purpose
The primary objective investigator-initiated trial will be prevention of respiratory failure in patients with COVID-19 infections.
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex not stated
Trial Details
Organisations
- Affiliations Kiniksa Pharmaceuticals
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Italy
- Focus Therapeutic Use
Interventions
Drugs | Route | Formulation |
---|---|---|
MavrilimumabPrimary Drug | Intravenous |
-
|
Mavrilimumab
Trial History
Event Date | Event Type | Comment |
---|---|---|
07 Apr 2020 | New trial record | New trial record Updated 07 Apr 2020 |
31 Mar 2020 | Other trial event | According to a Kiniksa Pharmaceuticals media release, Professor Lorenzo Dagna, MD, FACP (Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy) plans to initiate a prospective, single-center investigator-initiated study of Mavrilimumab, based on the initial results from the treatment protocol (n=6). Updated 07 Apr 2020 |
References
-
Kiniksa Pharmaceuticals. Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG